NetworkNewsBreaks – AnPac Bio-Medical Science Co

NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, initiated in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program. “Anpac Bio is proud to have received this accreditation,” said Dr. Pandit, the CLIA Laboratory director and CEO of Anpac Bio in the United States. “The College of American Pathologists (‘CAP’) is the gold standard in medical laboratory accreditation. Through this rigorous inspection process, CAP has certified that Anpac Bio is meeting the highest standards in quality patient care. We have strived from the beginning to lead the industry in quality and innovation. CAP certification is a major milestone along our journey to deliver on our promise of ground-breaking science and commercialization for our novel cancer differentiation analysis (‘CDA’) technology in the United States. We know that the CAP accreditation will only communicate further to our clients, research partners and future patients that Anpac Bio is committed to excellence and exceptional laboratory processes.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer